Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran

Mehdi Javanbakht* (Corresponding Author), Hamid R. Baradaran, Atefeh Mashayekhi, Ali Akbar Haghdoost, Mohammad E. Khamseh, Erfan Kharazmi, Aboozar Sadeghi

*Corresponding author for this work

Research output: Contribution to journalArticle

65 Citations (Scopus)
3 Downloads (Pure)

Abstract

Introduction: Diabetes is a worldwide high prevalence chronic progressive disease that poses a significant challenge to healthcare systems. The aim of this study is to provide a detailed economic burden of diagnosed type 2 diabetes mellitus (T2DM) and its complications in Iran in 2009 year.

Methods: This is a prevalence-based cost-of-illness study focusing on quantifying direct health care costs by bottom-up approach. Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, laboratory test, education and non-medical cost were collected from two national registries. The human capital approach was used to calculate indirect costs separately in male and female and also among different age groups.

Results: The total national cost of diagnosed T2DM in 2009 is estimated at 3.78 billion USA dollars (USD) including 2.04 +/- 0.28 billion direct (medical and non-medical) costs and indirect costs of 1.73 million. Average direct and indirect cost per capita was 842.6 +/- 102 and 864.8 USD respectively. Complications (48.9%) and drugs (23.8%) were main components of direct cost. The largest components of medical expenditures attributed to diabetes's complications are cardiovascular disease (42.3% of total Complications cost), nephropathy (23%) and ophthalmic complications (14%). Indirect costs include temporarily disability (335.7 million), permanent disability (452.4 million) and reduced productivity due to premature mortality (950.3 million).

Conclusions: T2DM is a costly disease in the Iran healthcare system and consume more than 8.69% of total health expenditure. In addition to these quantified costs, T2DM imposes high intangible costs on society in terms of reduced quality of life. Identification of effective new strategies for the control of diabetes and its complications is a public health priority.

Original languageEnglish
Article number26864
Number of pages7
JournalPloS ONE
Volume6
Issue number10
DOIs
Publication statusPublished - 31 Oct 2011

Fingerprint

cost of illness analysis
Cost of Illness
Medical problems
Iran
noninsulin-dependent diabetes mellitus
Type 2 Diabetes Mellitus
health care costs
diabetes
Costs and Cost Analysis
health services
Costs
drugs
kidney diseases
quality of life
physicians
cardiovascular diseases
education
public health
Diabetes Complications
eyes

Keywords

  • CORONARY-HEART-DISEASE
  • HEALTH-CARE COSTS
  • ECONOMIC BURDEN
  • RISK-FACTORS
  • COMPLICATIONS
  • PREVALENCE
  • POPULATION
  • GLUCOSE
  • US

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Javanbakht, M., Baradaran, H. R., Mashayekhi, A., Haghdoost, A. A., Khamseh, M. E., Kharazmi, E., & Sadeghi, A. (2011). Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. PloS ONE, 6(10), [26864]. https://doi.org/10.1371/journal.pone.0026864

Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. / Javanbakht, Mehdi (Corresponding Author); Baradaran, Hamid R.; Mashayekhi, Atefeh; Haghdoost, Ali Akbar; Khamseh, Mohammad E.; Kharazmi, Erfan; Sadeghi, Aboozar.

In: PloS ONE, Vol. 6, No. 10, 26864, 31.10.2011.

Research output: Contribution to journalArticle

Javanbakht, M, Baradaran, HR, Mashayekhi, A, Haghdoost, AA, Khamseh, ME, Kharazmi, E & Sadeghi, A 2011, 'Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran', PloS ONE, vol. 6, no. 10, 26864. https://doi.org/10.1371/journal.pone.0026864
Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E et al. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. PloS ONE. 2011 Oct 31;6(10). 26864. https://doi.org/10.1371/journal.pone.0026864
Javanbakht, Mehdi ; Baradaran, Hamid R. ; Mashayekhi, Atefeh ; Haghdoost, Ali Akbar ; Khamseh, Mohammad E. ; Kharazmi, Erfan ; Sadeghi, Aboozar. / Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran. In: PloS ONE. 2011 ; Vol. 6, No. 10.
@article{e12957908f414db6a72bf3fe2e3f6b56,
title = "Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran",
abstract = "Introduction: Diabetes is a worldwide high prevalence chronic progressive disease that poses a significant challenge to healthcare systems. The aim of this study is to provide a detailed economic burden of diagnosed type 2 diabetes mellitus (T2DM) and its complications in Iran in 2009 year.Methods: This is a prevalence-based cost-of-illness study focusing on quantifying direct health care costs by bottom-up approach. Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, laboratory test, education and non-medical cost were collected from two national registries. The human capital approach was used to calculate indirect costs separately in male and female and also among different age groups.Results: The total national cost of diagnosed T2DM in 2009 is estimated at 3.78 billion USA dollars (USD) including 2.04 +/- 0.28 billion direct (medical and non-medical) costs and indirect costs of 1.73 million. Average direct and indirect cost per capita was 842.6 +/- 102 and 864.8 USD respectively. Complications (48.9{\%}) and drugs (23.8{\%}) were main components of direct cost. The largest components of medical expenditures attributed to diabetes's complications are cardiovascular disease (42.3{\%} of total Complications cost), nephropathy (23{\%}) and ophthalmic complications (14{\%}). Indirect costs include temporarily disability (335.7 million), permanent disability (452.4 million) and reduced productivity due to premature mortality (950.3 million).Conclusions: T2DM is a costly disease in the Iran healthcare system and consume more than 8.69{\%} of total health expenditure. In addition to these quantified costs, T2DM imposes high intangible costs on society in terms of reduced quality of life. Identification of effective new strategies for the control of diabetes and its complications is a public health priority.",
keywords = "CORONARY-HEART-DISEASE, HEALTH-CARE COSTS, ECONOMIC BURDEN, RISK-FACTORS, COMPLICATIONS, PREVALENCE, POPULATION, GLUCOSE, US",
author = "Mehdi Javanbakht and Baradaran, {Hamid R.} and Atefeh Mashayekhi and Haghdoost, {Ali Akbar} and Khamseh, {Mohammad E.} and Erfan Kharazmi and Aboozar Sadeghi",
note = "This study was supported by a grant (number 358) from the Endocrine Research Center (Firoozgar) affiliated with Tehran University of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",
year = "2011",
month = "10",
day = "31",
doi = "10.1371/journal.pone.0026864",
language = "English",
volume = "6",
journal = "PloS ONE",
issn = "1932-6203",
publisher = "PUBLIC LIBRARY SCIENCE",
number = "10",

}

TY - JOUR

T1 - Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran

AU - Javanbakht, Mehdi

AU - Baradaran, Hamid R.

AU - Mashayekhi, Atefeh

AU - Haghdoost, Ali Akbar

AU - Khamseh, Mohammad E.

AU - Kharazmi, Erfan

AU - Sadeghi, Aboozar

N1 - This study was supported by a grant (number 358) from the Endocrine Research Center (Firoozgar) affiliated with Tehran University of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2011/10/31

Y1 - 2011/10/31

N2 - Introduction: Diabetes is a worldwide high prevalence chronic progressive disease that poses a significant challenge to healthcare systems. The aim of this study is to provide a detailed economic burden of diagnosed type 2 diabetes mellitus (T2DM) and its complications in Iran in 2009 year.Methods: This is a prevalence-based cost-of-illness study focusing on quantifying direct health care costs by bottom-up approach. Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, laboratory test, education and non-medical cost were collected from two national registries. The human capital approach was used to calculate indirect costs separately in male and female and also among different age groups.Results: The total national cost of diagnosed T2DM in 2009 is estimated at 3.78 billion USA dollars (USD) including 2.04 +/- 0.28 billion direct (medical and non-medical) costs and indirect costs of 1.73 million. Average direct and indirect cost per capita was 842.6 +/- 102 and 864.8 USD respectively. Complications (48.9%) and drugs (23.8%) were main components of direct cost. The largest components of medical expenditures attributed to diabetes's complications are cardiovascular disease (42.3% of total Complications cost), nephropathy (23%) and ophthalmic complications (14%). Indirect costs include temporarily disability (335.7 million), permanent disability (452.4 million) and reduced productivity due to premature mortality (950.3 million).Conclusions: T2DM is a costly disease in the Iran healthcare system and consume more than 8.69% of total health expenditure. In addition to these quantified costs, T2DM imposes high intangible costs on society in terms of reduced quality of life. Identification of effective new strategies for the control of diabetes and its complications is a public health priority.

AB - Introduction: Diabetes is a worldwide high prevalence chronic progressive disease that poses a significant challenge to healthcare systems. The aim of this study is to provide a detailed economic burden of diagnosed type 2 diabetes mellitus (T2DM) and its complications in Iran in 2009 year.Methods: This is a prevalence-based cost-of-illness study focusing on quantifying direct health care costs by bottom-up approach. Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, laboratory test, education and non-medical cost were collected from two national registries. The human capital approach was used to calculate indirect costs separately in male and female and also among different age groups.Results: The total national cost of diagnosed T2DM in 2009 is estimated at 3.78 billion USA dollars (USD) including 2.04 +/- 0.28 billion direct (medical and non-medical) costs and indirect costs of 1.73 million. Average direct and indirect cost per capita was 842.6 +/- 102 and 864.8 USD respectively. Complications (48.9%) and drugs (23.8%) were main components of direct cost. The largest components of medical expenditures attributed to diabetes's complications are cardiovascular disease (42.3% of total Complications cost), nephropathy (23%) and ophthalmic complications (14%). Indirect costs include temporarily disability (335.7 million), permanent disability (452.4 million) and reduced productivity due to premature mortality (950.3 million).Conclusions: T2DM is a costly disease in the Iran healthcare system and consume more than 8.69% of total health expenditure. In addition to these quantified costs, T2DM imposes high intangible costs on society in terms of reduced quality of life. Identification of effective new strategies for the control of diabetes and its complications is a public health priority.

KW - CORONARY-HEART-DISEASE

KW - HEALTH-CARE COSTS

KW - ECONOMIC BURDEN

KW - RISK-FACTORS

KW - COMPLICATIONS

KW - PREVALENCE

KW - POPULATION

KW - GLUCOSE

KW - US

UR - http://www.scopus.com/inward/record.url?scp=80055105303&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0026864

DO - 10.1371/journal.pone.0026864

M3 - Article

VL - 6

JO - PloS ONE

JF - PloS ONE

SN - 1932-6203

IS - 10

M1 - 26864

ER -